Compare Danaher Corporation (DHR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Tilray Brands Inc — how do they compare? Danaher Corporation trades at $201.03 (market cap $140.88B), while Tilray Brands Inc trades at $4.49 (market cap $540.74M). The key difference: Danaher Corporation is far larger — about 260.5× Tilray Brands Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| DHR | TLRY | |
|---|---|---|
Market Cap | $140.88B | $540.74M |
Sector | Health | Health |
52-Week High | $242.05 | $21.00 |
52-Week Low | $161.91 | $4.31 |
Enterprise Value | $153.66B | $637.89M |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
TLRY trades at $4.46, up 0.9% on the day, amid a bearish technical signal and mixed earnings history. The company reported a net loss of $2.19 billion in 2025, with a negative net income margin of -156.67%, though revenue grew to $821.31 million. Analyst consensus is cautious with 65% hold ratings, and recent news highlights expansion in medical cannabis and new product launches.
The outlook remains challenged by persistent losses and high debt levels, but low valuation ratios like P/S of 0.54 and P/B of 0.35 may attract value investors. Key risks include profitability struggles and regulatory uncertainty, while potential catalysts include international expansion and upcoming earnings on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
